Ovid Therapeutics raises $60M PIPE, reports positive OV329 data, expands indications, and clears OV4071 for Phase 1

Ovid Therapeutics Inc.

$60M PIPE: 19.15M shares at $2.01 and pre-funded warrants for 10.7M shares; closing expected March 19, 2026.
OV329 7 mg cohort: no treatment-related adverse events; Phase 2 for focal onset seizures planned for Q2 2026.
OV329 development expanded to tuberous sclerosis complex seizures (Q4 2026) and infantile spasms (2027).
OV4071 (oral KCC2 activator) received HREC/TGA approval; Phase 1 in Australia starts Q2 2026.
Cash $90.4M at Dec 31, 2025; net loss FY2025 $17.4M ($0.23/share); Series A warrants could add $53.9M.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Ovid Therapeutics Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at $60.0 million (effective 2026-03-17).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers named therein
Value: $60.0 million
Effective: 2026-03-17

Exact text from the filing

On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share

View on SEC.gov

310 material agreements filed in the last 30 days. Browse all material agreements →

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-019045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.